Department of Molecular Medicine and Medical Biotechnology, School of Medicine, University of Naples 'Federico II', Via S. Pansini 5, I-80131 Naples, Italy.
School of Medicine and Surgery, University of Naples 'Federico II', Via S. Pansini 5, I-80131 Naples, Italy.
Curr Med Chem. 2020;27(27):4536-4541. doi: 10.2174/0929867327666200416131117.
Here we report on the most recent updates on experimental drugs successfully employed in the treatment of the disease caused by SARS-CoV-2 coronavirus, also referred to as COVID-19 (COronaVIrus Disease-19). In particular, several cases of recovered patients have been reported after being treated with lopinavir/ritonavir [which is widely used to treat Human Immunodeficiency Virus (HIV) infection] in combination with the anti-flu drug oseltamivir. In addition, remdesivir, which has been previously administered to Ebola virus patients, has also proven effective in the U.S. against coronavirus, while antimalarial chloroquine and hydroxychloroquine, favipiravir and co-administered darunavir and umifenovir (in patient therapies) were also recently recorded as having anti-SARS-CoV-2 effects. Since the recoveries/deaths ratio in the last weeks significantly increased, especially in China, it is clear that the experimental antiviral therapy, together with the availability of intensive care unit beds in hospitals and rigorous government control measures, all play an important role in dealing with this virus. This also stresses the urgent need for the scientific community to devote its efforts to the development of other more specific antiviral strategies.
在这里，我们报告了最近在治疗由 SARS-CoV-2 冠状病毒引起的疾病（也称为 COVID-19）方面成功应用的实验性药物的最新进展。特别是，在联合使用抗流感药物奥司他韦治疗后，已经有几例康复患者的报道。此外，先前用于治疗埃博拉病毒患者的瑞德西韦在美国也被证明对冠状病毒有效，而抗疟疾药物氯喹和羟氯喹、法匹拉韦以及联合使用的达芦那韦和乌米酚（在患者治疗中）也最近被记录具有抗 SARS-CoV-2 的作用。由于最近几周的康复/死亡比例显著增加，特别是在中国，很明显，实验性抗病毒疗法，以及医院重症监护病房床位的可用性和政府严格的控制措施，都在应对这种病毒方面发挥了重要作用。这也强调了科学界迫切需要致力于开发其他更具针对性的抗病毒策略。
